Cite
HARVARD Citation
Visuri, I. et al. (2021). Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply. Alimentary pharmacology & therapeutics. 54 (6), pp. 848-849. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Visuri, I. et al. (2021). Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply. Alimentary pharmacology & therapeutics. 54 (6), pp. 848-849. [Online].